Inhibition of allergen-induced bronchospasm in patients with reversible bronchial obstruction by a new xanthone derivative.
Six patients with allergic asthma were studied in bronchial challenge tests with their specific antigen. In five cases 7ioxo-7-thiomethoxyxanthone-2-carboxylic acid, sodium salt (OTMX), a new xanthone with mediator-release inhibitory properties, given as an inhaled solution under 'single-blind' conditions, protected against the immediate-type bronchospastic response. This protection was statistically significant (p = 0.016) at the highest dose level used. Late reactions which occurred in two patients were unaffected by the compound.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000485:Allergens; D001249:Asthma / Q000188:drug therapy*; D001986:Bronchial Spasm / Q000276:immunology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D014966:Xanthenes / Q000008:administration & dosage / Q000627:therapeutic use*
D000485:Allergens; D010919:Placebos; D014966:Xanthenes